Is Cassava Sciences a Good Biotech Stock to Invest In?

: SAVA | Cassava Sciences, Inc. News, Ratings, and Charts

SAVA – Biotech company Cassava Sciences (SAVA) is known for its Alzheimer’s drug, currently in phase three clinical trials. The stock has gained triple digits so far this year. However, with the SEC investigating claims that the company allegedly manipulated its prior clinical trial results, is SAVA an ideal investment now? Read more to find out.

Biopharmaceutical company Cassava Sciences, Inc. (SAVA) shot to the limelight earlier this year following the positive results from clinical trials of its Alzheimer’s drug. SAVA gained 574% year-to-date on the prospect of becoming a leading drug developer for the disease, which affects one in nine people older than 65 years. The drug is currently in Phase three of clinical trials.

However, the company came under fire in August after a citizen petition was filed with the SEC, claiming that SAVA manipulated the clinical trial results. The stock plummeted 41.8% over the past six months and 34.8% over the past month.

Here’s what could shape SAVA’s performance in the near term:

SEC Investigations

SAVA is currently being investigated for alleged manipulation of clinical trial results for its Alzheimer’s drug. This follows a public petition filed with the U.S. FDA requesting the suspension of the clinical trials in August. Several doctors and medical journals have stated that there is no merit in these allegations. However, microbiologist and image-manipulation consultant Elisabeth Bik said, in an interview with the Wall Street Journal, that specific western blot images supporting SAVA’s Alzheimer’s drug appear to be photoshopped, along with certain other images in the published papers.

Besides the SEC, the National Institutes of Health, which funded SAVA’s drug development and trial, is also investigating the legitimacy of these data manipulation claims.

Lawsuits

Several shareholder rights law firms are currently investigating whether SAVA’s Board of Directors breached their fiduciary duties. Several class-action lawsuits have also been filed against the company, alleging that the company made false and misleading statements to the shareholders. The lawsuits allege that the company overstated its Alzheimer’s drug’s efficiency, the likelihood of the drug being approved by the FDA, thereby exaggerating its growth prospects.

POWR Ratings Reflect Bleak Prospects

SAVA has an overall F rating, which equates to Strong Sell in our proprietary POWR Ratings system. The POWR Ratings are calculated considering 118 different factors, with each factor weighted to an optimal degree.

SAVA has a grade of F for Quality and a D for Momentum and Sentiment. The company’s negative trailing-12-month ROE is in sync with the Quality. In addition, SAVA is currently trading below its 50-day and 200-day moving averages of $54.52 and $63.08, indicating a downtrend, justifying the Momentum grade. Furthermore, analysts expect the company’s EPS to remain negative until at least next year, accounting for the Sentiment grade.

Of the 473 stocks in the F-rated Biotech industry, SAVA is ranked #468.

In total, we rate SAVA on eight different levels. We have also rated SAVA for Growth, Stability, and Value. Click here to view all SAVA ratings.

Bottom Line

SAVA has vehemently denied the allegations that it manipulated its clinical results. However, the scientific community is still divided, with several medical professionals have stated that the published images might be photoshopped. With so much uncertainty surrounding his company, I believe the stock is best avoided now.

How Does Cassava Sciences, Inc. (SAVA) Stack Up Against its Peers?

While SAVA has an F rating in our proprietary rating system, you might want to consider looking at its industry peers, Sino Biopharmaceutical Limited (SBHMY), Otsuka Holdings Co Ltd. (OTSKY), and Vertex Pharmaceuticals Incorporated (VRTX), which have an A (Strong Buy) rating.

Want More Great Investing Ideas?

3 Stocks to DOUBLE This Year


SAVA shares were trading at $45.56 per share on Tuesday afternoon, up $0.71 (+1.58%). Year-to-date, SAVA has gained 568.04%, versus a 24.49% rise in the benchmark S&P 500 index during the same period.


About the Author: Aditi Ganguly


Aditi is an experienced content developer and financial writer who is passionate about helping investors understand the do’s and don'ts of investing. She has a keen interest in the stock market and has a fundamental approach when analyzing equities. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
SAVAGet RatingGet RatingGet Rating
SBHMYGet RatingGet RatingGet Rating
OTSKYGet RatingGet RatingGet Rating
VRTXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Investors: Are You Ready for November?

The S&P 500 (SPY) tumbled to end October. Is that a harbinger of more downside to come? Or will the bull market return with gusto? Investment pro Steve Reitmeister shares his time market views including a preview of his favorite stocks. Get the full story below...

3 Cybersecurity Stocks Defending Against Digital Threats

The demand for cybersecurity solutions is rising as digital threats and sophisticated cyberattacks continue to escalate. Therefore, it might be wise to keep track of cybersecurity stocks, CrowdStrike (CRWD), Palo Alto Networks (PANW), and Fortinet (FTNT), as they offer innovative solutions presenting further growth opportunities. Continue reading...

3 Oil Stocks With High Upside as Global Demand Rebounds

The outlook for oil demand growth appears promising despite economic uncertainties and worldwide supply deficit. Amid this, investing in quality oil stocks Enterprise Products Partners (EPD), Marathon Oil (MRO), and Plains All American Pipeline (PAA) could be ideal as global demand rebounds. Read more...

3 Tech Stocks Under $10 That Could Deliver Big Gains

The technology industry is booming, driven by breakthroughs and significant government investments. Thus, incorporating affordable tech stocks, Sprinklr (CXM), Sabre Corporation (SABR), and Cricut (CRCT) into your portfolio provides an accessible entry point to capitalize on the industry’s growth. Read more…

2 Concerns for Investors in October

The S&P 500 (SPY) may be touching all time highs...but recent action points to concerns on 2 fronts: inflation and earnings. Investment veteran Steve Reitmeister shares his views on these 2 timely topics along with a preview of his top stocks to buy now.

Read More Stories

More Cassava Sciences, Inc. (SAVA) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All SAVA News